PROTOCOLOS CLÍNICOS E DIRETRIZES TERAPÊUTICAS

Protocolos Clínicos e Diretrizes Terapêuticas 22. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol. 2004;15(1):148-56. 23. Provenzano R, Bhaduri S, Singh AK; PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol. 2005;64(2):113-23. 24. Pergola PE, Gartenberg G, Fu M, Wolfson M, Rao S, Bowers P. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia. Clin J Am Soc Nephrol. 2009;4(11):1731-40. Epub 2009 Sep 17. 25. Lee YK, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, et al. A comparison between once-weekly and twice- or thrice- weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study. Nephrol Dial Transplant. 2008;23(10):3240-6. Epub 2008 May 9. 26. Cody J, Daly C, Campbell M, et al. Frequency of administration of recombinant human erythropoietin for anaemia of end- stage renal disease in dialysis patients. Cochrane Database Syst Rev. 2005;(3):CD003895. 27. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med. 1998;339(9):578-83. 28. Messa P, Nicolini MA, Cesana B, Brezzi B, Zattera T, Magnasco A, et al. Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients. Nephrol Dial Transplant. 2006;21(2):431-6. Epub 2005 Oct 25. 29. Singh AK, Szczech L, Tang KL, Banhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-98. 30. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2006;(4):CD003967. 31. Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Arch Intern Med. 2009;169(12):1104-12. 32. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol. 2009;4(4):755-62. Epub 2009 Apr 1. 33. Tolman C, Richardson D, Bartlett C, Will E. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol. 2005;16(5):1463-70. Epub 2005 Mar 23. 34. Brimble KS, Rabbat CG, McKenna P, Lambert K, Carlisle EJ. Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial. J Am Soc Nephrol. 2003;14(10):2654-61. 35. Patterson P, Allon M. Prospective evaluation of an anemia treatment algorithm in hemodialysis patients. Am J Kidney Dis. 1998;32(4):635-41. 36. Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant. 2007;22(3):794-800. Epub 2007 Jan 8. 66